SuperGen to Present at Lazard Healthcare Conference on November 16th

DUBLIN, Calif.--(BUSINESS WIRE)-- SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that James S.J. Manuso, Ph.D., President and Chief Executive Officer, will present at the Lazard Capital Markets 7th Annual Healthcare Conference on Tuesday, November 16th in New York.

SuperGen's presentation will begin at 4:40 p.m. ET. A live webcast of the presentation will be available in the Investor Events section of the Company's Web site at www.supergen.com. The webcast will be archived for 30 days.

About SuperGen

SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. For more information about SuperGen, please visit http://www.supergen.com.



CONTACT:

SuperGen, Inc.
Timothy L. Enns, 925-560-2810
Senior Vice President
Corporate Communications & Business Development
[email protected]
or
Susanna Chau, 925-560-2845
Manager
Investor Relations
[email protected]

KEYWORDS:   United States  North America  California  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.